Similar articles

• Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.

  Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. Boonstra JJ, et al. J Natl Cancer Inst. 2010 Feb 24;102(4):271-4. doi: 10.1093/jnci/djp499. Epub 2010 Jan 14. J Natl Cancer Inst. 2010. PMID: 20075370 Free PMC article.
• Multi-kinase inhibitors create buzz at ASCO.

  Branca MA. Branca MA. Nat Biotechnol. 2005 Jun;23(6):639. doi: 10.1038/nbt0605-639. Nat Biotechnol. 2005. PMID: 15940222 No abstract available.
• Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.

  Keswani RN, Chumsangsri A, Mustafi R, Delgado J, Cohen EE, Bissonnette M. Keswani RN, et al. Dis Esophagus. 2008;21(6):514-21. doi: 10.1111/j.1442-2050.2007.00799.x. Dis Esophagus. 2008. PMID: 18840136
• Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

  Sulkes A. Sulkes A. Isr Med Assoc J. 2010 Oct;12(10):628-32. Isr Med Assoc J. 2010. PMID: 21090521 Review.
• Sorafenib.

  Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Recent Results Cancer Res. 2010. PMID: 20072831 Review.